Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 163

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 163
---
 market share now exceeds that of Lantus. Sales slowly increased in the United States, mainly due to the withdrawal of a competing medicine. Sales of Fabrazyme reached € 1,047 million in 2024 ( + 9.1% CER ), propelled by the Rest of World region due to growth in the number of patients. Lovenox sales decreased by 7.0% CER to € 982 million, reflecting impacts from volume-based procurement (VBP) in China and from biosimilar competition in Europe. Plavix sales decreased by 0.4% CER to € 914 million due to a deceleration of market share in the Rest of the World region, partially offset by volume growth in China from VBP inclusion.

| SANOFIFORM 20-F2024 | 75 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

Cerezyme sales rose by 20.3% CER to € 742 million, reflecting growth in high-inflation countries (Argentina and Turkey) included in the Rest of the World region. Sales of Myozyme/Lumizyme decreased by 12.3% CER in 2024 to € 671 million, reflecting switches to Nexviazyme/Nexviadyme as mentioned above. In 2024 , sales of Alprolix amounted to € 588 million, up 9.6% CER , driven by the Rest of the World region and the United States. Thymoglobulin sales rose by 7.3% CER to €492 million, driven by the United States and the Rest of the World region. Net sales of Praluent for 2024 reached € 483 million, up 15.2% CER , underpinned by Europe and the Rest of the World region . Sales of Aubagio were down 59.4% CER at € 379 million, reflecting the loss of exclusivity in the United States in March 2023 followed by Europe in September 2023. Eloctate posted sales of € 368 million in 2024 , down 20.8% CER , reflecting switches to ALTUVIIIO. Cerdelga sales were € 333 million, up 12.8% , underpinned by continued growth in the United States and Europe. Vaccines In 2024 , Vaccines sales were up 11.0% on a reported basis and 13.